The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125483171 12548317 1 I 20140528 20160712 20160712 EXP NO-PFIZER INC-2381331 PFIZER 32.00 YR M Y 0.00000 20160712 OT NO NO

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125483171 12548317 1 PS PREDNISOLONE. PREDNISOLONE 1 Oral 40 MG/M2, (DAY 1-29, TAPER TO DAY 35) U 0 40 MG/M**2
125483171 12548317 2 SS PREDNISOLONE. PREDNISOLONE 1 Intrathecal 10 MG, UNK U 0 10 MG
125483171 12548317 3 SS PREDNISONE. PREDNISONE 1 Intrathecal 10 MG, UNK UNK 0 10 MG
125483171 12548317 4 SS PREDNISONE. PREDNISONE 1 Oral 40 MG/M2, UNK UNK 0 40 MG/M**2
125483171 12548317 5 C VINCRISTINE SULFATE. VINCRISTINE SULFATE 1 Intravenous (not otherwise specified) 1.5 MG/M2, MAX 2.0 MG UNK 0 1.5 MG/M**2
125483171 12548317 6 C CYTARABINE. CYTARABINE 1 Intrathecal 40 MG, UNK UNK 0 40 MG
125483171 12548317 7 C CYTARABINE. CYTARABINE 1 Intravenous (not otherwise specified) 200 MG/M2, UNK UNK 0 200 MG/M**2
125483171 12548317 8 C DOXORUBICIN HCL DOXORUBICIN HYDROCHLORIDE 1 Intravenous (not otherwise specified) 30 MG/M2, UNK UNK 0 30 MG/M**2
125483171 12548317 9 C METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Intrathecal 15 MG, UNK UNK 0 15 MG
125483171 12548317 10 C METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Intravenous (not otherwise specified) 1500 MG/M2, UNK UNK 0 1500 MG/M**2
125483171 12548317 11 C CYCLOPHOSPHAMIDE. CYCLOPHOSPHAMIDE 1 Intravenous (not otherwise specified) 750 MG/M2, UNK UNK 0 750 MG/M**2
125483171 12548317 12 C DAUNORUBICIN DAUNORUBICIN 1 Intravenous (not otherwise specified) 50 MG/M2, UNK UNK 0 50 MG/M**2
125483171 12548317 13 C G-CSF GRANULOCYTE COLONY-STIMULATING FACTOR NOS 1 10 MCG/KG/DAY UNK 0
125483171 12548317 14 C L-ASPARAGINASE ASPARAGINASE 1 Intravenous (not otherwise specified) 10000 IU, UNK UNK 0 10000 IU
125483171 12548317 15 C MERCAPTOPURINE. MERCAPTOPURINE 1 Oral 35 MG/M2, UNK UNK 0 35 MG/M**2
125483171 12548317 16 C THIOGUANINE THIOGUANINE 1 Intravenous (not otherwise specified) 150 MG/M2, UNK UNK 0 150 MG/M**2

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125483171 12548317 1 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 3 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 5 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 11 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 12 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 13 Peripheral blood stem cell apheresis
125483171 12548317 14 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 15 Precursor T-lymphoblastic lymphoma/leukaemia
125483171 12548317 16 Precursor T-lymphoblastic lymphoma/leukaemia

Outcome of event

Event ID CASEID OUTC COD
125483171 12548317 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125483171 12548317 Osteonecrosis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found